Earnings summaries and quarterly performance for TriSalus Life Sciences.
Executive leadership at TriSalus Life Sciences.
Board of directors at TriSalus Life Sciences.
Research analysts who have asked questions during TriSalus Life Sciences earnings calls.
JW
Justin Walsh
Jones Trading
3 questions for TLSI
Also covers: ACHV, BLRX, GTBP +6 more
SK
Suraj Kalia
Oppenheimer & Co. Inc.
3 questions for TLSI
Also covers: ABT, AORT, ATRC +14 more
William Plovanic
Canaccord Genuity
3 questions for TLSI
Also covers: ATRC, CBLL, CVRX +9 more
Frank Takkinen
Lake Street Capital Markets
2 questions for TLSI
Also covers: ANGO, AORT, AXGN +17 more
Bill Plovanic
Canaccord Genuity
1 question for TLSI
Also covers: ANGO, AORT, CBLL +7 more
CB
Carl Burns
Analyst
1 question for TLSI
Also covers: NUTX
JW
Jason Wittes
Roth Capital Partners, LLC
1 question for TLSI
Also covers: ALUR, ARAY, ATEC +13 more
MP
Matthew Park
Cantor Fitzgerald
1 question for TLSI
Also covers: AXGN, BVS, CERS +5 more
Nelson Cox
Lake Street Capital Markets
1 question for TLSI
Also covers: AORT, AQST, CVRX +6 more
RO
Ross Osborn
Cantor Fitzgerald
1 question for TLSI
Also covers: AXGN, CERS, CVRX +12 more
Shaymus Contorno
Oppenheimer & Co. Inc.
1 question for TLSI
Also covers: LMAT, VREX
Recent press releases and 8-K filings for TLSI.
TriSalus Life Sciences Announces Preliminary Q4 and Full-Year 2025 Results and 2026 Revenue Guidance
TLSI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- TriSalus Life Sciences, Inc. announced preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, and provided 2026 revenue guidance.
- For Q4 2025, the company anticipates revenues of approximately $13.2 million, marking approximately 60% growth year-over-year.
- Full-year 2025 revenues are expected to be approximately $45.2 million, representing approximately 53% growth year-over-year, which exceeded its 2025 guidance.
- The company set initial 2026 revenue guidance in the range of approximately $60 million to $62 million.
- As of December 31, 2025, cash and cash equivalents are estimated at approximately $20.4 million.
Jan 12, 2026, 12:09 PM
TriSalus Life Sciences Announces Preliminary Q4 and Full-Year 2025 Results and 2026 Revenue Guidance
TLSI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- TriSalus Life Sciences reported preliminary fourth quarter 2025 revenue of approximately $13.2 million, representing a 60% year-over-year increase.
- Preliminary full-year 2025 revenue reached approximately $45.2 million, exceeding its 2025 guidance with approximately 53% year-over-year growth.
- The company set initial 2026 revenue guidance in the range of approximately $60-$62 million.
- As of December 31, 2025, TriSalus estimated cash and cash equivalents of approximately $20.4 million.
Jan 12, 2026, 12:00 PM
TriSalus Life Sciences Highlights Pressure-Enabled Drug Delivery Technology and Thyroid Artery Embolization Application
TLSI
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- TriSalus Life Sciences' platform technology modulates pressure and flow to deliver 40%-500% more therapy into solid tumors and has received a unique reimbursement code from CMS due to demonstrated benefits, including a 50% reduction in post-procedure readmissions.
- The company currently holds less than a 10% share in the liver embolization market, which is approximately $500 million, but is expanding its technology's application to other embolization procedures.
- A significant new market opportunity is Thyroid Artery Embolization (TAE) for multinodular goiter, representing an additional $400 million market opportunity.
- Pressure-enabled TAE, utilizing TriSalus' technology, has achieved a 73% volume reduction in hyperthyroid patients, which is the largest reported in literature, offering a less invasive alternative to surgery for patients with large goiters and hyperthyroidism.
Dec 15, 2025, 7:00 PM
TriSalus Life Sciences Highlights New Applications for Pressure-Enabled Drug Delivery Technology
TLSI
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- TriSalus Life Sciences is focused on improving outcomes for patients with solid tumors in the liver, pancreas, and other solid tumors, utilizing a platform technology that modulates pressure and flow to deliver therapy more effectively into tumors and prevent off-target delivery.
- The company's TriNav catheter technology has demonstrated significant benefits, including delivering 40%-500% more therapy into tumors and achieving a 50% reduction in patient readmissions post-procedure, which led to unique reimbursement from CMS.
- TriSalus is expanding its technology's application beyond the liver, with a notable new approach for thyroid artery embolization (TAE) for multinodular goiter, a $400 million market opportunity, innovated by Dr. Juan Camacho.
- Dr. Camacho's pressure-enabled TAE (PETAE) method, which uses the TriNav microcatheter, aims to reduce the risk of non-target embolization by accessing only the inferior thyroid artery and has shown promise in initial studies involving 22 patients.
- TriSalus is actively building more robust data for PETAE through the multi-center PROTECT Registry, which currently has 12 interested sites and has acquired 25% of its sample as of the document published on 2025-12-15.
Dec 15, 2025, 7:00 PM
Trisalus Highlights Pressure-Enabled Thyroid Artery Embolization (PETAE) at KOL Event
TLSI
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- Trisalus (TLSI) focuses on improving outcomes for patients with solid tumors in the liver, pancreas, and other solid tumors, using a platform technology that modulates pressure and flow to enhance therapy delivery and prevent off-target effects.
- The company's technology, which currently holds less than 10% share in a sub-$500 million liver market, is being expanded to new embolization applications.
- A new Pressure-Enabled Thyroid Artery Embolization (PETAE) approach, developed using Trisalus's technology, offers a minimally invasive alternative for multinodular goiter, addressing an additional $400 million market opportunity.
- Initial clinical results for PETAE demonstrated a 71% euthyroid conversion rate in hyperthyroid patients and a 73% gland volume reduction, with only grade one complications observed.
- Trisalus's core technology has secured a unique reimbursement code from CMS due to its proven ability to deliver more drug to tumors and reduce patient readmissions by 50%.
Dec 15, 2025, 7:00 PM
TriSalus Life Sciences Provides 2025 Outlook and Q3 2025 Financial Highlights
TLSI
Guidance Update
Product Launch
New Projects/Investments
- TriSalus Life Sciences reported Q3 2025 revenue of $11.6 million and projects 50% revenue growth with gross margins >85% for 2025. The company ended Q3 2025 with $22.7 million in cash and aims for Adjusted EBITDA positivity by early to mid-2026.
- The company's Pressure Enabled Drug Delivery (PEDD™) technology addresses a device market opportunity exceeding $2.5 billion, supported by unique procedural reimbursement codes, such as $17,957 for the C9797 treatment code in 2025.
- Upcoming milestones include the launch of TriNav XP for Uterine Fibroid Embolization and TriNav Advance in Q4 2025, alongside anticipated Q4 2025 data readouts for Nelitolimod Phase 1 proof of concept in Uveal Melanoma Liver Metastases and Locally Advanced Pancreatic Cancer.
- TriSalus maintains a robust intellectual property position with 79 registered patents and 95 pending patent applications, securing market exclusivity until 2040.
Dec 11, 2025, 9:00 PM
TriSalus Life Sciences Highlights High-Growth, High-Margin Business and New Applications
TLSI
New Projects/Investments
Revenue Acceleration/Inflection
Guidance Update
- TriSalus Life Sciences (TLSI) is an oncology-focused company that utilizes a catheter-based technology for targeted drug delivery to tumors, operating in a $2.5 billion market opportunity and currently growing in excess of 50% per year with 85% to 90% gross margins.
- The company has favorable reimbursement, including a proprietary HCPCS code for pressure-enabled drug delivery, which saves CMS $8,000 per procedure due to a 50% reduction in 30-day hospital readmissions.
- TLSI has expanded its product portfolio with new device sizes and is pursuing new applications beyond liver embolization, such as uterine fibroids, multinodular goiter, pancreatic technology, and genicular artery embolization.
- The company has guided for 50% growth this year (2025) and aims for Adjusted EBITDA positivity by mid-year (2026), with an operating expense run rate between $55 million and $60 million.
Dec 2, 2025, 8:10 PM
TriSalus Life Sciences Details Oncology Technology, Market Expansion, and Financial Outlook
TLSI
Product Launch
Guidance Update
Revenue Acceleration/Inflection
- TriSalus Life Sciences is an oncology-focused company with a high-margin, high-growth drug technology that delivers more to tumors, addressing a $2.5 billion market opportunity.
- Its catheter-based system utilizes pressure-enabled drug delivery, increasing drug concentration in tumors by 50%-500% and leading to improved patient outcomes and reduced complications.
- The company benefits from a proprietary HCPCS code for its pressure-enabled drug delivery, which provides favorable reimbursement for hospitals (up to $40,000 per procedure) and generates $8,000 in savings for CMS per procedure due to reduced readmissions.
- TriSalus is expanding its market penetration with a full portfolio of devices and is developing data for new applications beyond liver embolization, including uterine fibroids, multinodular goiter, pancreatic technology, and genicular artery embolization.
- The company reports over 50% annual growth with 85%-90% gross margins and is focused on achieving Adjusted EBITDA positivity by mid-year, driven by reduced R&D and G&A spend.
Dec 2, 2025, 8:10 PM
TriSalus Life Sciences Highlights Market Opportunity, Product Expansion, and Financial Outlook
TLSI
Revenue Acceleration/Inflection
Product Launch
Guidance Update
- TriSalus Life Sciences is an oncology-focused company with a drug delivery technology for tumors, operating in a $2.5 billion market opportunity in the liver.
- The company's technology is experiencing significant growth, projected to be in excess of 50% per year for the current year, with 85%-90% gross margins.
- TriSalus has secured a proprietary reimbursement code (HCPCS) for its pressure-enabled drug delivery, which results in $8,000 in savings for CMS per procedure due to reduced readmissions.
- The company launched two new device sizes in 2025, completing its product portfolio, and is expanding into new applications such as uterine fibroids, multinodular goiter, and pancreatic technology.
- TriSalus aims for Adjusted EBITDA positivity by mid-year (2026), driven by reduced R&D and G&A spend, and reported a cash burn of $3.8 million in the last quarter.
Dec 2, 2025, 8:10 PM
TriSalus Life Sciences Reports Q3 Earnings and Discusses Growth Strategy
TLSI
Earnings
Product Launch
Revenue Acceleration/Inflection
- TriSalus Life Sciences, an oncology company, reported Q3 earnings of $11.6 million and anticipates Q4 to be its strongest quarter of the year.
- The company's pressure-enabled drug delivery technology has secured favorable reimbursement from CMS, including its own procedural codes, contributing to 50% annual growth and an 85% gross margin in a $2.5 billion market opportunity.
- New product launches, such as TriNav Flex, have seen rapid adoption, now representing 45% of the portfolio since its June launch, with another new technology planned for December.
- The company's cash operating expenses are approximately $12 million per quarter, with a break-even revenue target of about $14 million per quarter.
Nov 20, 2025, 7:30 PM
Quarterly earnings call transcripts for TriSalus Life Sciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more